News >

Expert Shares Insight on Liquid Biopsies in Pediatric Sarcomas

Brandon Scalea
Published: Monday, Jul 30, 2018

Brian D. Crompton, MD

Brian D. Crompton, MD

Liquid biopsies are a way to better understand the mutational spectrum of a cancer across multiple disease sites, as the approach captures the signature of any part of a tumor throughout the body, explained Brian D. Crompton, MD.

, Crompton provided insight on the debate of liquid versus tissue biopsies, particularly in the setting of pediatric patients with sarcomas.

OncLive: Can you speak to the use of liquid biopsies in pediatric sarcomas?

Crompton: [We utilize] liquid biopsies to get a better understanding of the biology around metastatic disease and how it develops in pediatric bone sarcomas. The idea is that pediatric tumors in patients release both ctDNA and, sometimes, actual tumor cells into the bloodstreams of patients. Obviously, you can collect those samples very easily with a blood draw and identify ctDNA by detecting the mutations that are actually present in the tumor itself.

The other thing that can happen is that you may not find anything to target in the area you biopsied. There might still be targetable mutations in all the other metastatic sites. We really have no idea. When a patient gets marked up, they're not getting biopsies from multiple sites. Therefore, in the end, we believe a liquid biopsy will give us a better general picture of the pattern of mutation across the burden of disease, not just one specific spot.

What are some of the challenges in getting physicians to adopt liquid biopsies?

I don't think there are a lot of challenges. One of the hurdles in trying to implement anything patient related is you have to convince people that there is potential. We're not asking physicians or patients to provide something that's dangerous. Getting a simple blood draw is minimally invasive, which is the whole point.

However, to have them come in and give an extra tube of blood, and to get [all] physicians to do it takes a bit of incentive. That incentive is the promise of understanding the disease better. In previous years, we were basically relying on leftover specimens from studies that had been ongoing for decades.

Now that we have these data to say, "Look, this isn't science fiction; this is actually doable," we're now able to actually embed collection protocols into all the trials going on. Off the top of my head, we are probably involved in a dozen trials where we have included language on how to specifically take samples. We need to better understand ctDNA and heterogeneity.

Will the advancements seen in liquid biopsies, in terms of collecting ctDNA, result in more patients getting enrolled on clinical trials?

It is important to say that we haven't yet proven that this is going to work. However, you can easily imagine that it will make it easier for patients to enroll on studies, and perhaps even bypass the need for patients—when they have recurring disease—to get a surgical procedure to verify what was present before. It could potentially make it a lot easier, but we're still talking 5 years from now or even further down the road.


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x